6U2F

PCSK9-Fab 7G7 complex bound to cis-1-amino-4-phenylcyclohexaneacyl-WNLK(hR)IGLLR - NH2

Summary for 6U2F

• Entry DOI: 10.2210/pdb6u2f/pdb
• Related PRD ID: PRD_002363
• Descriptor: Proprotein convertase subtilisin/kexin type 9, Organo-peptide PCSK9 inhibitor, 7G7 heavy chain, ... (6 entities in total)
• Functional Keywords: inhibitor, complex, hydrolase-hydrolase inhibitor-immune system complex, hydrolase/hydrolase inhibitor/immune system
• Biological source: Homo sapiens (Human); More
• Total number of polymer chains: 4
• Total formula weight: 124811.30

Authors

Ultsch, M.H.,Kirchhofer, D. (deposition date: 2019-08-19, release date: 2020-02-05, Last modification date: 2023-11-15)

Primary citation

Burdick, D.J.,Skelton, N.J.,Ultsch, M.,Beresini, M.H.,Eigenbrot, C.,Li, W.,Zhang, Y.,Nguyen, H.,Kong-Beltran, M.,Quinn, J.G.,Kirchhofer, D.
Design of Organo-Peptides As Bipartite PCSK9 Antagonists.
Acs Chem.Biol., 15:425-436, 2020

PubMed Abstract: Proprotein convertase subtilisin/kexin 9 (PCSK9) has become an important therapeutic target for lipid lowering, since it regulates low-density lipoprotein cholesterol (LDL-c) levels by binding to liver LDL receptors (LDLR) and effecting their intracellular degradation. However, the development of small molecule inhibitors is hampered by the lack of attractive PCSK9 target sites. We recently discovered helical peptides that are able to bind to a cryptic groove site on PCSK9, which is situated in proximity to the main LDLR binding site. Here, we designed potent bipartite PCSK9 inhibitors by appending organic moieties to a helical groove-binding peptide to reach a hydrophobic pocket in the proximal LDLR binding region. The ultimately designed 1-amino-4-phenylcyclohexane-1-carbonyl extension improved the peptide affinity by >100-fold, yielding organo-peptide antagonists that potently inhibited PCSK9 binding to LDLR and preserved cellular LDLR. These new bipartite antagonists have reduced mass and improved potency compared to the first-generation peptide antagonists, further validating the PCSK9 groove as a viable therapeutic target site.

PubMed: 31962046
DOI: 10.1021/acschembio.9b00899

Experimental method

X-RAY DIFFRACTION (2.94 Å)